| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/02/2008 | WO2008050673A1 Adhesive skin patch |
| 05/02/2008 | WO2008050600A1 Therapeutic or preventive agent for intractable disease based on oxidative stress-mediated cell death as molecular background |
| 05/02/2008 | WO2008050200A1 Oxadiazole compounds as calcium channel antagonists |
| 05/02/2008 | WO2008049997A2 Indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| 05/02/2008 | WO2008049996A2 Novel indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| 05/02/2008 | WO2008049994A1 New fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone hsp 90 |
| 05/02/2008 | WO2008049864A1 Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
| 05/02/2008 | WO2008049785A1 Ih channel inhibitors for the promotion of wakefulness |
| 05/02/2008 | WO2008049226A1 Inhibition of sox9 function fn the treatment of proteogl ycan-associated pathophysiological conditions |
| 05/02/2008 | WO2008049157A1 Combination therapy |
| 05/02/2008 | WO2008019971A3 Arylpiperazine derivatives and uses thereof |
| 05/02/2008 | WO2008002946A3 Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist |
| 05/02/2008 | WO2007150010A3 Cyclopropyl amine derivatives as histamin h3 receptor modulators |
| 05/02/2008 | WO2007147892A3 Use of inducer of promyelocytic leukemia protein (pml) for treating polyglutamine expansion neurodegenerative diseases |
| 05/02/2008 | WO2007061868A3 Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors |
| 05/02/2008 | CA2667582A1 Method of treating conditions associated with proteoglycan production |
| 05/02/2008 | CA2667553A1 Methods and combination therapies for treating alzheimer's disease |
| 05/02/2008 | CA2667545A1 Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
| 05/02/2008 | CA2667536A1 Highly purified type a botulinum toxin preparation from infant botulism pathogen |
| 05/02/2008 | CA2667397A1 Oleanane triterpene saponin compounds which are effective on treatment of dementia and mild cognitive impairment (mci), and improvement of cognitive function |
| 05/02/2008 | CA2667260A1 Intracerebral oxidation inhibitor and use thereof |
| 05/02/2008 | CA2667231A1 Process for selectively localizing active ingredients on and in mitochondria and corresponding active ingredients |
| 05/02/2008 | CA2667052A1 Combination therapy |
| 05/02/2008 | CA2666606A1 Preventing or reducing oxidative stress or oxidative cell injury by the administration of a water-insoluble cellulose derivative |
| 05/02/2008 | CA2666497A1 Novel indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| 05/02/2008 | CA2665710A1 Ih channel inhibitors for the promotion of wakefulness |
| 05/02/2008 | CA2664115A1 New fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone hsp 90 |
| 05/01/2008 | US20080103306 preparation of an imidazole derivative of formula I,** Image-1wherein R1, R2, R3 and R4 are described hereinabove. These compounds can be used in the treatment or prevention of mGluR5 receptor mediated disorders. and treatment of pain, psychosis and memory deficits |
| 05/01/2008 | US20080103213 Curcumin analog or metabolite microencapsulated by a polyethylene glycolated liposome of dimyristoyl phosphatidylcholine, cholesterol, and dimyristoyl phsphatidylethanolamine; anticarcinogenic agents; parenteral colloidal drug delivery system providing improved bioavailability |
| 05/01/2008 | US20080103209 Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists |
| 05/01/2008 | US20080103200 Levodopa prodrugs, and compositions and uses thereof |
| 05/01/2008 | US20080103197 Alkyl-, alkenyl- and alkynylcarbamate derivatives, their preparation and their application in therapeutics |
| 05/01/2008 | US20080103196 19-hydroxylabda-8(17)-en-16,15-olide; mushroom extraction; MTT assay; neuroprotectant; cortical neuron damages, Alzheimer's disease; analgesic, antiinflammatory,anticarcinogenic, hypotensive agent |
| 05/01/2008 | US20080103191 Entacapone-derivatives |
| 05/01/2008 | US20080103189 Preparation and utility of substituted indoles |
| 05/01/2008 | US20080103188 Novel bicyclic compounds as modulators of androgen receptor function |
| 05/01/2008 | US20080103180 CCR9 inhibitors and methods of use thereof |
| 05/01/2008 | US20080103179 For treating diabetes, hypertension, migraine, epilepsy, sleep apnea, depression, impulse control disorders or alcohol addiction; coadministering a sympathomimetic agent such as phentermine and an anticonvulsant sulfamate or sulfonylurea, preferably topiramate or zonisamide; side effect reduction |
| 05/01/2008 | US20080103178 N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives |
| 05/01/2008 | US20080103177 New use of iloperidone |
| 05/01/2008 | US20080103176 N-{1-(3,5-Difluoro-benzyl)-3-[7-(2,2-dimethyl-propyl)-2-piperidin-1-yl-1,2,3,4-tetrahydro-naphthalen-1-ylamino]-2-hydroxy-propyl}-acetamide; 13-secretase inhibitor; Alzheimer's disease; inhibitors of beta-secretase, that inhibit beta-secretase-mediated cleavage of amiloid precursor protein APP |
| 05/01/2008 | US20080103173 Compounds Having Activity At Nk3 Receptor And Uses Thereof In Medicine |
| 05/01/2008 | US20080103172 as tyrosine, serine/threonine, cyclin-dependent kinases, HER protein; 5-{2-[3-[4-trifluoromethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazol-2-yl]-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrazol-4-yl]-vinyl}-pyridine-3-carbaldehyde; antiproliferative, antiinflammatory agent, neurodegenerative diseases |
| 05/01/2008 | US20080103170 Nicotinic Acetylcholine Receptor Ligands |
| 05/01/2008 | US20080103166 Administering tropisetron to prevent and treat Schizophrenia, Alzheimer's, Parkinson's, and Huntington's Diseases,Tourette's Syndrome and Attention deficit disorder; antidepressants, anxiolytic and antiepileptic agents |
| 05/01/2008 | US20080103159 Composition Comprising Ocaperidone |
| 05/01/2008 | US20080103158 Methods for treating delaying the progression of alzheimer's disease with heterocyclic compounds |
| 05/01/2008 | US20080103157 3,3-dibenzylimidazo[1,2-a]pyridin-2(3H)-one; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally |
| 05/01/2008 | US20080103154 3, 4-dihydro-2(IH)-quinolinone and 2(1H)-quinolinone derivatives |
| 05/01/2008 | US20080103147 Highly selective norepinephrine reuptake inhibitors and methods of using the same |
| 05/01/2008 | US20080103146 Highly Selective Norepinephrine Reuptake Inhibitors And Methods Of Using The Same |
| 05/01/2008 | US20080103145 Administering racemic reboxetine component |
| 05/01/2008 | US20080103142 c-Jun N-terminal kinase and cyclin-dependent kinase inhibitor; (4-benzotriazol-1-yl-5-chloro-pyrimidin-2-yl)-cyclohexyl-amine; antiinflammatory and anticarcinogenic agent; autoimmune and neurodegenerative disorders; rheumatoid arthritis, asthma, type II diabetes, Alzheimer's and Parkinson's diseases |
| 05/01/2008 | US20080103137 antiinflammatory agents; 1H-imidazo[4,5-b]pyridin-7-indole-2-yl- derivatives; autoimmune and proliferative disorders; inhibitors of cell adhesion molecule expression and inflammatory cytokine signal transduction; rheumatoid arthritis, ulcerative colitis/Crohn's disease, central nervous system diseases |
| 05/01/2008 | US20080103135 Histamine H3 antagonists; do not contain imidazolyl moiety; such as 1-[4-(4-piperidin-1-ylmethyl-phenyl)-but-3-ynyl]-piperidine |
| 05/01/2008 | US20080103134 Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine |
| 05/01/2008 | US20080103133 4-OXO-2,3,4,5-TETRAHYDRO-BENZO[b][1,4]DIAZEPINE DERIVATIVES |
| 05/01/2008 | US20080103132 Fused heterocyclic compounds |
| 05/01/2008 | US20080103131 Therapeutically Active Thiophenepyrimidinone Compounds and Their Use |
| 05/01/2008 | US20080103129 Heterocyclic derived metalloprotease inhibitors |
| 05/01/2008 | US20080103128 Lactams substituted by cyclic succinates as inhibitors of abetta protein production |
| 05/01/2008 | US20080103127 Methods for treating disruptive behavior disorders |
| 05/01/2008 | US20080103126 2-[[3-(2-benzo[b]thiophen-5-yl-ethoxy)propyl](methyl)amino]-1-ethanol; antihypoxic agent; synergistic mixture with acetylcholine esterase inhibitor (Tacrine, Donepezil, Rivastigmine); neurodegenerative diseases, ischemic cerebral lesion, cerebral apoplexy, Alzheimer's disease, cognition activator |
| 05/01/2008 | US20080103110 Water soluble prodrugs comprising therapeutics coupled via metabolically cleavable ester bond to proteins; extended blood half life; cancer, inflammation, infection, pain |
| 05/01/2008 | US20080103107 Screening Methods |
| 05/01/2008 | US20080103105 Nervous system, neurodegenerative, and psychological disorders are treated using synergistic mixture of neurogenic agents; atorvastatin, cerivastatin, fluvastatin, simvastatin, lovastatin, pravastatin, rosuvastatin, or crilvastatin; and buspirone, ribavirin, tacrine, azakenpaullone, or folic acid |
| 05/01/2008 | US20080103102 Therapeutic compositions and methods of treatment with capsianoside-type compounds |
| 05/01/2008 | US20080102121 exhibit a bimodal or multimodal release profile; solid oral dosage forms |
| 05/01/2008 | US20080102090 Mixture with surfactant; therapy for muscular paralysis; greater intramuscular safety margin; selective action on inhibition of pain-related (nociceptive) nerve cell function |
| 05/01/2008 | US20080102060 Methods of using bcl-2 for the therapeutic treatment and prevention of diseases |
| 05/01/2008 | US20080102055 Method for detecting Alzheimer's disease |
| 05/01/2008 | US20080102031 4-[(4-N,N-diethylaminocarbonyl)phenyl]-spiro[2H,1-benzopyran-2,4'-piperidine; ligands of delta opioid receptor; analgesic, anxiolitic, antidepressant, analgesic; gastrointestinal disorders, neurodegenerative diseases; side effect reduction |
| 04/30/2008 | EP1916304A2 Antigenic polypeptides associated with multiple sclerosis and uses |
| 04/30/2008 | EP1916247A1 Activator of peroxisome proliferator activated receptor |
| 04/30/2008 | EP1916241A1 Crystal of phenylalanine derivative, process for producing the same and use thereof |
| 04/30/2008 | EP1915994A1 Cyclic amine derivative containing ppar regulator |
| 04/30/2008 | EP1915992A1 Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence |
| 04/30/2008 | EP1915379A1 Olanzapine analogs and methods of use thereof |
| 04/30/2008 | EP1915377A1 Pyrazolo pyrimidines useful as aurora kinase inhibitors |
| 04/30/2008 | EP1915375A1 Derivatives of 5-pyridinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics |
| 04/30/2008 | EP1915363A1 Oxopyridyl quinoline amides as nk3 receptor modulators |
| 04/30/2008 | EP1915362A1 Amide alkyl pyridiyl quinolines as nk3 receptor modulators |
| 04/30/2008 | EP1915361A1 Alkylpyridyl quinolines as nk3 receptor modulators |
| 04/30/2008 | EP1915357A1 2-hydroxy-propionic acid derivatives and 3-hydroxy-benzofuran-2-one derivatives with affinity for the gaba-b-receptor |
| 04/30/2008 | EP1915356A1 Therapeutic agents |
| 04/30/2008 | EP1915355A1 Therapeutic agents |
| 04/30/2008 | EP1915352A1 Compounds for the treatment of alzheimer's disease |
| 04/30/2008 | EP1915348A1 Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands |
| 04/30/2008 | EP1915345A1 Fluoro substituted 2-oxo azepan derivatives |
| 04/30/2008 | EP1915339A1 Beta-secretase inhibitors for use in the treatment of alzheimer's disease |
| 04/30/2008 | EP1915156A2 Method of treating parturient placental mammals in order to reduce maternal and/or utirine exhaustion |
| 04/30/2008 | EP1915146A2 Novel 1-aryl-3-azabicycloý3.1.0¨hexanes: preparation and use to treat neuropsychiatric disorders |
| 04/30/2008 | EP1915145A1 Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory |
| 04/30/2008 | EP1915144A2 Method to reduce oxidative damage and improve mitochondrial efficiency |
| 04/30/2008 | EP1915142A1 Composition comprising oleic acid and the use thereof |
| 04/30/2008 | EP1713791B1 5-fluoro- and chloro-pyridin-2-yl-tetrazoles as ligands of the metabotropic glutamate receptor-5 |
| 04/30/2008 | EP1615936A4 Phosphates of secondary alcohols |
| 04/30/2008 | EP1397161B1 Compounds comprising an analgesic molecule linked to a vector |
| 04/30/2008 | EP1196156B1 Transnasal anticonvulsive compositions |
| 04/30/2008 | EP1165613B1 Melanocortin receptor ligands |